Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.
Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.
Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.
Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.
Registry search results
Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-10-07 18:53 UTC. Counts are registry matches, not unique peptides or a worldwide total.
Phase not reported / not applicableCompletedOBSERVATIONAL
Start: 2021-06-02. Completion: 2024-12-15 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Xultophy® (insulin degludec/liraglutide) (drug) — also listed as: insulin degludec/liraglutide
Where the study takes place — 32 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Daejeon, Cheongsa-ro, Seo-gu, South Korea
Explore the world’s study registries
These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.
SGLT2 inhibitor (drug) — also listed as: dapagliflozin, empagliflozin, canagliflozin
Tirzepatide (drug)
Other drugs (drug) — also listed as: ARBs, ACE inhibitors, Metformin, DPP4i, non steroidal mineralocorticoid receptor agonists
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Vithas Valencia Consuelo Valencia, Valencia, Spain Site recruitment: Recruiting
Start: 2022-11-25. Completion: 2025-10-24 (may be estimated). No results posted in this registry response.
Products and interventions (0)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University Hospital Basel, Endocrinology, Diabetes and Metabolism Basel, Switzerland Site recruitment: Not reported
Start: 2025-05-08. Completion: 2027-01 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Liraglutide (drug) — also listed as: Victoza, Saxenda
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States Site recruitment: Recruiting
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Cleveland Clinic Weston, Florida, United States Site recruitment: Not reported
Cleveland Clinic Cleveland, Ohio, United States Site recruitment: Not reported
Start: 2025-03-29. Completion: 2028-06-30 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Metformin (drug)
Triple Therapy of Other Oral Antidiabetic Drugs (drug)
ganagliflozin (drug)
liraglutide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Tianjin Medical University General Hospital Tianjin, Tianjin Municipality, China Site recruitment: Recruiting
Start: 2021-07-01. Completion: 2025-03-12 (may be estimated). Results are posted in this registry.
Products and interventions (14)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
SU (drug)
DPP4 (drug)
SGLT2i (drug)
GLP-1RA (drug)
SGLT2i or GLP-1RA (drug)
Linagliptin (DPP4) (drug)
Exenatide (GLP-1RA) (drug)
Liraglutide (GLP-1RA) (drug)
Empagliflozin (SGLT2i) (drug)
Glimepiride (SU) (drug)
Glipizide (SU) (drug)
Glimepiride (SU) or Glipizide (SU) (drug)
SU or DPP4 (excluding saxagliptin and alogliptin) (drug)
Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) (drug)
Where the study takes place — 6 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Kaiser Permanente Southern California Pasadena, California, United States Site recruitment: Not reported
Romain S. Neugebauer Pleasanton, California, United States Site recruitment: Not reported
Kaiser Permanente Hawaii Honolulu, Hawaii, United States Site recruitment: Not reported
Henry Ford Health System Detroit, Michigan, United States Site recruitment: Not reported
HealthPartners Institute Bloomington, Minnesota, United States Site recruitment: Not reported
Geisinger Danville, Pennsylvania, United States Site recruitment: Not reported
Start: 2025-10-03. Completion: 2029-03-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Liraglutide Pen Injector (drug) — also listed as: Liraglutide
Saline Injections (other) — also listed as: Placebo
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Mayo Clinic in Rochester Rochester, Minnesota, United States Site recruitment: Recruiting
Start: 2024-05-27. Completion: 2025-07-18 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
NEX-22A, a prolonged release formulation of liraglutide (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Profil Neuss, Germany Site recruitment: Not reported
Start: 2025-09-15. Completion: 2029-06-30 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Intervention (drug)
Active Comparator (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Ohio State University Columbus, Ohio, United States Site recruitment: Not reported
Binge Eating Disorder Associated With Obesity; Binge Eating Disorder; Eating Disorder Binge; Eating Disorders; GLP-1; CBT; Obesity &Amp; Overweight
Sponsor
Haukeland University Hospital
Countries with listed sites
Norway
Registry dates and results
Start: 2025-07-01. Completion: 2028-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
GLP-1 (drug)
CBTe Group Therapy (behavioral)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Haukeland University Hospital Bergen, Vestland, Norway Site recruitment: Recruiting
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO New Orleans, Louisiana, United States Site recruitment: Not reported
Ochsner Health System - Biospecimen New Orleans, Louisiana, United States Site recruitment: Not reported
Atrial Fibrillation; Recurrence; Overweight and Obesity; Liraglutide
Sponsor
University Hospital Birmingham
Countries with listed sites
United Kingdom
Registry dates and results
Start: 2022-04-17. Completion: 2026-06-01 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Liraglutide plus upstream risk factors modification advice and consultation (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University Hospitals Birmingham NHS Foundation Trust Birmingham, West Midlands, United Kingdom Site recruitment: Not reported
Start: 2016-11. Completion: 2026-10-01 (may be estimated). No results posted in this registry response.
Products and interventions (7)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Metformin (drug) — also listed as: Glucophage
Gliclazide (drug) — also listed as: Diamicron, Diamicron MR
Sitagliptin (drug) — also listed as: Januvia
Liraglutide (drug) — also listed as: Victoza
Pioglitazone (drug) — also listed as: Actos
Dapagliflozin (drug) — also listed as: Forxiga, Farxiga
human insulin (drug) — also listed as: novorapid, glargine
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Hamad Medical Corporation Doha, Qatar, Qatar Site recruitment: Not reported
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
University of Miami Miami, Florida, United States Site recruitment: Not reported
Start: 2022-08-09. Completion: 2023-10-31 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
4P-004 (drug) — also listed as: Liraglutide
Placebo (drug) — also listed as: NaCl
Where the study takes place — 3 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
UCL-St Luc Brussels, Belgium Site recruitment: Not reported
AZMaria Middelares Ghent, Belgium Site recruitment: Not reported
UZ Leuven Leuven, Belgium Site recruitment: Not reported
Diabetes Mellitus, Type 2; Cardiovascular Diseases
Sponsor
Janssen Research & Development, LLC
Countries with listed sites
United States
Registry dates and results
Start: 2018-02-22. Completion: 2018-06-25 (may be estimated). No results posted in this registry response.
Products and interventions (9)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Canagliflozin (drug)
Empagliflozin (drug)
Dapagliflozin (drug)
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (drug)
Glucagon-like Peptide-1 (GLP-1) Agonist (drug)
Anti-hyperglycemic Agents (AHA) (drug)
Thiazolidinediones (TZD) (drug)
Sulfonylureas (SU) (drug)
Insulin (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Janssen Investigative Site Titusville, New Jersey, United States Site recruitment: Not reported
Start: 2025-05-22. Completion: 2029-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Liraglutide and metformin (drug)
Metformin (drug)
Where the study takes place — 3 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
Peking University Third Hospital Beijing, Beijing Municipality, China Site recruitment: Recruiting
Beijing Obstetrics and Gynecology Hospital Beijing, China Site recruitment: Not yet recruiting
Haidian District Maternal and Child Health Care Hospital Beijing, China Site recruitment: Not yet recruiting
Start: 2012-05. Completion: 2023-08-03 (may be estimated). Results are posted in this registry.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Liraglutide (drug) — also listed as: Victoza
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
UBMD Pediatrics, Division of Pediatric Endocrinology Buffalo, New York, United States Site recruitment: Not reported
Start: 2024-05-20. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Degludec insulin (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
continuous glucose monitoring system（CGMS） Beijing, Beijing Municipality, China Site recruitment: Not reported
Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.
